Zasocitinib is an investigational oral TYK2 inhibitor that is thought to treat plaque psoriasis by blocking inflammatory pathways in the body. The Latitude Atlas Study is comparing zasocitinib to an approved TYK2 inhibitor called deucravacitinib to see if it may provide a clearer future for people living with psoriasis.
Join us in a quest to explore the future of psoriasis care.
What if you could potentially impact the 125 million people worldwide (2–3% of the entire population) with psoriasis?1 Embrace the future of psoriasis care with the LATITUDE Psoriasis Studies.
Participation in clinical research for psoriasis has an impact on 125 million people worldwide (2–3% of the entire population) with psoriasis.1 Explore a different path for psoriasis with the Latitude Atlas Study.
The purpose of this study is to evaluate an investigational oral treatment (taken by mouth), zasocitinib, to see if it works better in reducing the symptoms of moderate to severe plaque psoriasis than an approved oral treatment, deucravacitinib.
Zasocitinib is thought to work by helping to control inflammatory signals known to contribute to the buildup of plaque psoriasis. Participants will receive zasocitinib or deucravacitinib while completing various study tests and procedures. All study treatments will be given as oral pills.
Neither participants nor the study staff will know which treatment they are receiving. Participants will attend up to 9 scheduled study visits over the course of about 6 months.
You are now leaving latitudeatlas.com and being redirected to a website that is not operated by Clinical Trial Media Inc.
